Sixty women were postmenopausal selected from the outpatient Gynecology Hospital Santa Marcelina that passed by routine consultations and fulfilling the inclusion criteria were invited to the study.
The women were randomly allocated to control or experimental group (30 in each group) in a double-blind controlled clinical trial.
The control group received the same tablet with the organoleptic characteristics of Tenavit® for a period of 4 months.

Sixty women were postmenopausal selected from the outpatient Gynecology Hospital Santa Marcelina that passed by routine consultations and fulfilling the inclusion criteria were invited to the study.
The experimental group received one tablet of Tenavit® (pyridoxine hydrochloride 4.00mg + folic acid 0.80mg + cyanocobalamin 0.40 mg) daily and the placebo group received the same tablet with the organoleptic characteristics of Tenavit® for a period of 4 months.

Menopause

Dyslipidemias

Homocystinaemia

The experimental group received one tablet of Tenavit® daily for a period of 4 months.

Tenavit®

Placebo group received the same tablet with the organoleptic characteristics of Tenavit® for a period of 4 months.

Placebo Oral Tablet

Website of the Ministry of Health with mortality tables

Effect of Polyvitaminics (Pyridoxine Hydrochloride, Folic Acid and Cyanocobalamin) in the Concentration of Homocysteine and Lipid Profile in Postmenopausal Women: a Randomized Controlled, Double-blind Clinical Trial

supplementation may be beneficial in postmenopausal patients, with the intention to reduce the level of homocysteine and, thus, reduce the cardiovascular risk in this age.

Carolina Vicente Banzoli

Principal Investigator

Casa de Saúde santa Marcelina

End Stage Renal Disease

Renal Failure

PAL-40 Active

PAL-40 Placebo

VA Medical Center, Birmingham

Health Economics Resource Center (HERC), Menlo Park

VA Palo Alto Health Care System

VA San Diego Healthcare System, San Diego

VA Eastern Colorado Health Care System, Denver

VA Connecticut Health Care System (West Haven)

VA Medical Center, DC

VA Medical Center, Bay Pines

North Florida/South Georgia Veterans Health System

VA Medical Center, Miami

West Palm Beach VA Medical Center

Edward Hines, Jr. VA Hospital

Richard Roudebush VA Medical Center, Indianapolis

Southeast Veterans Healthcare System, New Orleans

VA Medical Center, Jamaica Plain Campus

VA Ann Arbor Healthcare System

John D. Dingell VA Medical Center, Detroit

VA Medical Center, Minneapolis

G.V. (Sonny) Montgomery VA Medical Center, Jackson

VA Medical Center, Kansas City MO

VA Medical Center, Bronx

VA Western New York Healthcare System at Buffalo

New York Harbor HCS

VA Medical Center, Northport

VA Medical Center, Syracuse

VA Medical Center, Cleveland

VA Medical Center, Dayton

VA Medical Center, Portland

VA Pittsburgh Health Care System

Ralph H Johnson VA Medical Center, Charleston

VA Medical Center, Memphis

VA North Texas Health Care System, Dallas

Michael E. DeBakey VA Medical Center (152)

Hunter Holmes McGuire VA Medical Center

VA Puget Sound Health Care System, Seattle

Zablocki VA Medical Center, Milwaukee

VA Medical Center, San Juan

Homocysteine Study (HOST)

CSP #453 - Homocysteinemia in Kidney and Endstage Renal Disease Study (HOST)

Jamison, Rex - Study Chair

US Department of Veterans Affairs

Pan American Laboratories

Abbott Diagnostics Division

Stroke

Cerebral Infarction

Myocardial Infarction

pyridoxine

cyanocobalamin

folic acid multivitamin

Wake Forest University School of Medicine

Vitamin Therapy for Prevention of Stroke

Vitamin Intervention for Stroke Prevention

National Institute of Neurological Disorders and Stroke (NINDS)

infarction

pyridoxine/infarction

Effect of Polyvitaminics (Pyridoxine Hydrochloride, Folic Acid and Cyanocobalamin) in the Concentration of Homocysteine and Lipid Profile in Postmenopausal Women: a Randomized Controlled, Double-blind Clinical Trial

Homocysteine Study (HOST)

Vitamin Therapy for Prevention of Stroke

Najkompletnija baza ljekovitog bilja potpomognuta znanošću